Healthcare Industry News: vascular access
News Release - January 17, 2008
Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and MarketingMOUNTAIN VIEW, Calif., Jan. 17 (HSMN NewsFeed) -- Cardiva Medical, Inc., a privately held medical device company and developer of the Boomerang Catalyst(TM) System is pleased to announce the addition of two officers to their management team. Malcolm Farnsworth joins Cardiva as Vice President of Finance and Chief Financial Officer. Tara Zerby joins Cardiva as Vice President of Business Development and Marketing.
"We are very excited to have Malcolm and Tara join Cardiva during this exciting stage in the company," says Augustine Lien, Chairman and CEO. "Their expertise in the medical device industry will be beneficial in the growth of our company."
Malcolm Farnsworth joined Cardiva in January 2008. Previously, Mr. Farnsworth served as Executive Vice President and Chief Financial Officer at POINT Biomedical Corporation, a specialty pharmaceutical company developing pharmaceutical imaging agents to detect coronary artery disease. Prior to that, he served as Vice President of Finance and Chief Financial Officer at Gynecare, Inc., a medical device company, that was acquired by Johnson & Johnson after its IPO in 1996. Before that he served as Vice President of Finance and Chief Financial Officer at Origin Medsystems, a minimally invasive surgical device company that was acquired by Eli Lilly and merged into Guidant. Mr. Farnsworth holds an M.B.A. degree from the Haas School, University of California at Berkeley and a B.S. degree in Business and Economics from Lehigh University.
Tara L. Zerby joined Cardiva in November 2007. Ms. Zerby brings with her over 25 years of experience in sales, marketing and management in the medical device industry. Prior to joining Cardiva, she served as Vice President and General Manager of RTI-Cardiovascular, formerly the Alabama Tissue Center. Ms. Zerby operated her own consulting firm, assisting start-up medical device companies. She was also the executive Director of Marketing and Clinical Applications for Stereotaxis, Inc., Business Unit Director, Surgical Systems and Director of Global Sales for Cryocath Technologies. Ms. Zerby holds an M.B.A. from University of Wisconsin, an M.A. from Georgia State and a B.A. from Wake Forest.
About Cardiva Medical, Inc.
Founded in July 2002, and headquartered in Mountain View, Calif., Cardiva Medical, Inc. is a privately held medical company focused on developing and commercializing vascular access site management and closure devices with unsurpassed safety and ease-of-use. Cardiva's first product, the Boomerang Wire System, was approved in EU countries and in the US in 2004. Cardiva's second-generation product, the Boomerang Catalyst System, was approved in March 2007 and launched in July 2007. The enhanced Boomerang Catalyst, trade named as "Boomerang Catalyst II System" received 510(K) clearance in September 2007 and launched in January 2008. Cardiva was selected by Frost & Sullivan as the recipient of the 2006 Frost & Sullivan Award for Entrepreneurial Company in the U.S. angioplasty and vascular closure devices market. For additional information about Cardiva Medical, Inc. see our website at http://www.cardivamedical.com.
Cardiva, Boomerang and Boomerang Catalyst System are trademarks/registered trademarks of Cardiva Medical, Inc.
Source: Cardiva Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.